-mutated tumors. Even so, just a fraction of these clients responds to immune checkpoint or PARP inhibitors as well as individuals that do respond typically develop resistance and relapse. Seviteronel (developmental codes VT-464 and, formerly, INO-464) is really an experimental cancer medication